Biogen has agreed to acquire Apellis Pharmaceuticals after an extended negotiation process. The company also entered a collaboration with Alloy Therapeutics focused on antisense drug development using ...

Biogen has agreed to acquire ​Apellis ​Pharmaceuticals ​for about $5.6 billion in cash, expanding its portfolio ⁠of ‌rare-disease medicines.

Biogen Inc (NASDAQ:BIIB) reported upbeat earnings for the third quarter on Wednesday. The company pisted third-quarter adjusted EPS of $4.08, down 6%, beating the consensus of $3.79. The company ...

Biogen has forged a settlement with investors who claimed the company misled them in describing how it gained a controversial ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the first quarter of 2025 adjusted earnings per share was $3.02. That’s down from $3.67 a year ago, beating the analyst consensus of $2.52. The ...

Oct 2 (Reuters) - In a rare – and possibly unique – turn of events, both pharmacy company Biogen (BIIB.O), opens new tab and its shareholders have asked a federal appeals court to grant mid-case ...

Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer signals ...

Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth. The ...

If you are wondering whether Biogen's current share price offers value or risk, it helps to first look at how the stock has been behaving and what recent news might mean for its long term prospects.

AI-generated summary reviewed by our newsroom. Read our AI Policy. Biogen plans to beef up its Research Triangle Park operations with $2 billion in new local spending, the company announced Monday.

Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results , but sales fell by 7.1% year on year to $2.28 billion. Its non-GAAP profit of $1.99 per share was 22.1% above analysts’ consensus ...

Biogen Inc. forecast 2026 profit above Wall Street’s expectations, signaling that steep cost-cutting measures are cushioning the impact of shrinking sales from its multiple sclerosis franchise.